Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology

March 20, 2024

Previous